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Wolman’s Syndrome. SOS was clinically diagnosed and treatment
began between 7 and 37 days post-HSCT (mean17 days). Pa-
tients were treated per protocol with a starting dose of 10 mg/kg/
day with subsequent increases of 10 mg/kg/day until clinically
therapeutic to a max of 60 mg/kg/day (exception:  2 y/o popu-
lation allowed a maximum of 100 mg/kg/day, n1). The duration
of deﬁbrotide treatment ranged from 13 to 31 days (mean18
days).There were no signiﬁcant complications related to the deﬁ-
brotide infusions or therapy. Seven of 11 (63.6%) patients showed
complete response to the therapy, while 4 patients were classiﬁed
as non-responders. The 100 day post-HSCT survival rate was
54.5% (6/11) for all patients. In conclusion, this study provides
further evidence that deﬁbrotide is an efﬁcacious and safe treat-
ment for pediatric SOS occurring after HSCT.
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CIFIC RECEPTORS; EFFECTS IN PATIENTS WITH NEUROBLASTOMA
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ton, TX; 2Dept of Pediatrics, Baylor College of Medicine, Houston, TX;
3Dept of Medicine, Baylor College of Medicine, Houston, TX.
Long-term survival for children with neuroblastoma remains
poor despite intensiﬁcation of therapy. Neuroblastoma cells ex-
press a number of potential target antigens for the immune re-
sponse including GD2 and T cells engineered to express chimeric
antigen receptors (CAR) for these antigens might supplement
conventional therapeutics. Unfortunately, modiﬁcation of primary
T cells with CAR has demonstrated limited functionality and
persistence in vivo, likely because the target tumor cells lack the
co-stimulatory molecules required for T cell activation. We have
previously shown that Epstein Barr Virus speciﬁc cytotoxic T
lymphocytes (EBV-CTLs) persist and function in vivo long term,
in part because they receive co-stimulation from EBV infected B
lymphocytes. We reasoned that EBV-CTLs engineered to express
GD2-CAR would also receive such co-stimulatory signals follow-
ing engagement of their native (EBV-speciﬁc) receptors, and hence
would persist longer than primary T cells expressing the same
CAR. We therefore developed a Phase I clinical study to directly
compare EBV CTL-CAR and T-cell CAR. We used two retroviral
vectors distinguishable by a non-expressed marker sequence so that
signal detected in vivo could be assigned to the CTL or the T cells.
Vector use was alternated between the two cell populations. To
date 3 patients received 210E7/m2 of each cell population, while
4 have received 110E8/m2 of each product. We observed no
adverse effects. Even at the low cell doses used to date, signal could
be detected for 6 weeks in peripheral blood. Differential quantita-
tive PCR analysis of the signal showed that EBV-CTL CAR were
present at a higher level and persisted longer than primary T cell
associated CAR. Clinically there has been one mixed response and
two with stable disease, while one patient treated in CR remains
disease free at 12 months. 4 patients have died of progressive
disease. Expressing chimeric antigen receptors in virus speciﬁc T
cells appears to improve lymphocyte survival after adoptive transfer
compared to CAR expression in primary T cells, and may thereby
increase the therapeutic potential of these cells. It will be of interest
to use this approach early after stem cell transplantation, when
residual malignant cells are at their lowest level, and homeostatic
signals will favor expansion of adoptively transferred engineered
CTL.
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EFFECTIVE IMMUNOTHERAPY FOR NEUROBLASTOMA REQUIRES HSCT
AND T CELL TRANSFER
Orentas, R.J.1,2, Jing, W.1,2, Yan, X.1,2, Johnson, B.D.1,2 1Medical
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We have employed a mouse model for neuroblastoma, AGN2a
cells injected subcutaneously in to strain A/J mice, to demon-
strate that transfection of AGN2a with CD80, CD86, CD54,
and CD137L transforms this lethal cell line in to an effective
cell-based vaccine (AGN2a-4P). When tumor vaccines are ad-
ministered in the context of Treg blockade (with anti-CD25
antibody), the anti-tumor effect is heightened. Our previous
work also demonstrated that the inclusion of CD137L in the
vaccine preparation is uniquely responsible for a strong anti-
tumor T cell response. However, when we switched from tu-
mor-challenge to tumor-bearing regimens the vaccine was in-
effective. Even the inclusion of gene expression vectors
encoding GM-CSF, IL-15, lymphotactin, or SLC did not in-
hibit tumor progression. In order to determine if any impact
could be made in tumor-bearing animals, we initiated a tumor-
bearing model system featuring HSCT. Analysis of lymphoid
reconstitution post-HSCT revealed that up to day 21, mice
remained severely lymphopenic. However, it was during this
time period that vaccination with AGN2a-4P proved most ef-
fective in a tumor-challenge experiment. Moreover, vaccination
early post-HSCT was markedly improved when T cells were
adoptively transferred 3 days after HSCT, just prior to the
initiation of AGN2a-4P vaccination. ELISPOT data with puri-
ﬁed CD4 and CD8 cells indicated that adoptively transferred
lymphocytes early post-conditioning generated an IFN--pro-
ducing tumor-speciﬁc effector population. Furthermore, splenic
reconstitution studies at day 21 clearly indicated that animals
given lymphocyte adoptive transfer had greater percentages of
donor (as opposed to residual host) T cells in their spleens. This
indicates that combining adoptive T cell transfer with HSCT
alters the lymphocyte populations present early post-HSCT,
and that these populations are crucial to the generation of
anti-tumor effector cells. We then tested our post-HSCT vac-
cine strategy in a tumor-bearing model. 1 105 live tumor cells
were given on day -8, TBI on day -1, HSCT consisting of bone
marrow plus 6 106 T cells on day 0, and irradiated AGN2a-4P
vaccine on days 2 and 7. Effective neuroblastoma therapy re-
quired HSCT, T cell transfer and AGN2a-4P vaccination. Our
results support the current practice of autologous HSCT for
neuroblastoma therapy, and suggest that the addition of vacci-
nation and adoptive immunotherapy (T cell transfer) to these
regimens may improve outcomes.
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The role of reduced intensity conditioning (RIC) regimens in
pediatric pts is unclear. To deﬁne the feasibility and toxicity of
this approach using multiple stem cell sources in pediatric pts
ineligible for myeloablative transplant, we conducted a trial at
25 centers participating in the Pediatric Blood and Marrow
Transplant Consortium (PBMTC). Thirty two pediatric pts
(age 2-20yrs, med 12) have been enrolled to date with the
following stem cell sources: 7 related donor (RD) BM (2 mis-
matched); 5 RD-PBSC; 9 unrelated donor (UD) BM; 4UD-
PBSC; 7 UD-CB. Qualifying indications included a previous
allogenic (n15) or autologous (n4) transplant, severe organ
toxicity (n5), invasive fungal infection (n2), and other co-
morbidities, (n 6 pts, 4 with Down syndrome). Diagnoses
included ALL (4 CR2; 9 CR3), AML (6 CR2; 3 CR3; 1 second-
ary), MLL (1 CR3), HD (2 CR3), B-NHL (1 PR3), MDS (2 RA;
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1 secondary RA; 1 RAEB in CR1), and JMML (1 PR3). Patients
received busulfan 0.8mg/kg/dose IV x 8 doses (target AUC
900-1100 uM/min), ﬂudarabine 30mg/m2/d x 6 days, and thy-
moglobulin, 2.5 mg/m2/d x 1 day for RD and x 4 days for UD
and UCB. Two pts rejected their grafts, one after a mismatched
RD-BM, and a second after UD-BM. Two pts died prior to day
100 due to toxicity (6%) and the overall NRM is 16%. Acute
GVHD (grade I-II) occurred in 3/25 (12%, no grade III-IV) and
chronic GVHD occurred in 4/18 (22%) evaluable pts. Median
follow up is 12 months (range 1-35 m). Of 30 pts 30 days out
from transplant, 10 pts relapsed. Two year EFS and OS are 49%
(SE 9.8) and 49% (SE 11%), respectively. Two relapsed pts are
alive at 5 and 1 months after a second transplant and DLI,
respectively. One patient who rejected received a second RIC,
engrafted, and is alive with cGVHD. Of the 8 pts surviving
more than one year from transplant, 4 had AML/MDS (2 in
CR2; 1 secondary AML; 1 secondary MDS), 3 had ALL (1 in
CR2; 2 in CR3,), and 1 had HD in CR3. In conclusion, RIC
using bu/ﬂu/ATG in a large cooperative group setting leads to
engraftment in 90% of very high risk pediatric pts using a
variety of stem cell sources. In spite of signiﬁcant prior therapy
and comorbidities in this cohort, rates of NRM and GVHD are
low. Prolonged relapse free survival has occurred not only in pts
with myeloid disease as expected, but also in pts with ALL and
lymphoma. Flu/bu/ATG is a promising therapeutic approach
for pediatric pts otherwise ineligible for myeloablative trans-
plant.
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Relapse and NRM after allogeneic SCT remain signiﬁcant bar-
riers to success in treating very high-risk ALL. Preclinical models
have shown activity of SRL against human ALL, causing apoptosis
and cell death at serum levels used for immune suppression. We
hypothesized that SRL would decrease relapse after HSCT for
ALL, with acceptable rates of GVHD, thus improving EFS. This
multi-center pilot trial assessed the feasibility/toxicity of SRL-
based GVHD prophylaxis in RD, UD, and UCB HSCT. After a
preparative regimen of TBI, thiotepa and cyclophosphamide, pts
received continuous IV tacrolimus (start d-2, target 5-10ng/mL),
PO sirolimus (start d0, target 3-12ng/mL), and IV methotrexate
(MTX; 5mg/m2, d1,3, and6 plus d11 for recipients of UD
BM/PBSC). Tacrolimus was tapered between d42-96 for MSD
and d100-180 for others. Sirolimus was tapered over 4 wks
starting at 6m after transplant. Thirty two patients have been
enrolled, with a median age of 9 yrs (1-18). Immunophenotypes
included pre-B 24, T-cell 7, and MLL 1. Six patients were in VHR
CR1, 17 were in CR2 (9 CR1 18 months), and 8 were in CR3.
Stem cell sources included UCB 16, MSD-BM 14, 5/6 mismatched
RD-BM 1, 9/10 mismatched UD-PBSC 1. SRL was successfully
administered to all pts and therapeutic drug levels achieved. Four
patients had SRL held brieﬂy for high levels or toxicity and three
patients stopped due to toxicity (VOD/TAM). Engraftment oc-
curred in 29 of 31 evaluable pts at median of 20d (13-62); one CB
recipient engrafted successfully after a second infusion and a sec-
ond patient relapsed prior to engraftment. Overall grade II-III
aGVHD occurred in 11/31 evaluable pts (35%, no grade IV). 4/19
(21%) of evaluable patients developed cGVHD. Relapses occurred
in 5 pts at a median of 94 days (34-362). NRM occurred in 3
patients (9%). Other signiﬁcant toxicities included one pt with IPS
requiring intubation (resolved), one nonfatal VOD, one pericardial
effusion, and two cases of reversible TAM. With a median f/u of
9m (1-38m) the 1 yr EFS and OS are 71.4% (SE 10.6) and 80.3%
(SE 7.2), respectively. In this very high risk cohort of children with
ALL, we have demonstrated that GVHD prophylaxis with SRL,
tacrolimus, and MTX is feasible using multiple stem cell sources,
resulting in low rates of NRM, acute and chronic GVHD, and
relapse. A randomized phase III trial comparing this regimen to
tacrolimus/MTX in children undergoing HSCT for ALL is open-
ing soon through the Children’s Oncology Group.
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A NOVEL ANTIBODY-BASED MINIMAL INTENSITY CONDITIONING REG-
IMEN FOR CHILDREN WITH SEVERE ORGAN TOXICITY OR DNA REPAIR
DISORDERS
Rao, K.1, Hale, G.2, Brenner, M.K.3, Davies, G.E.1, Veys, P.1,
Amrolia, P.J.1 1Great Ormond Street Children’s Hospital, London,
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Children with severe organ toxicities, DNA repair disorders
and infants 1 year tolerate existing conditioning regimens,
including reduced intensity conditioning, poorly. To reduce
TRM in such patients, we used a minimal intensity conditioning
regimen utilising 2 rat anti-CD45 monoclonal antibodies
(Mabs) YTH24.5/YTH 54.12 for myelosuppression and Ale-
mtuzumab (anti-CD52) for immunosuppression. As CD45 is
expressed selectively on haemopoietic cells, the Mabs provide
immunosuppression and transient myeloablation without the
systemic toxicity associated with chemotherapy. 14 children (5
SCID, 5 CID, 2 dyskeratosis congenita, 1 reticular dysgenesis, 1
HLH) were transplanted at a median age of 13 months (5
months-11 years). Inclusion criteria were primary immunodeﬁ-
ciency (PID) in children age 1 (n7), severe organ toxicity
(n12) and DNA repair defects/radiation sensitivity (n4). Do-
nors were MSD (n4), MUD (n9) and MMUD (n2). Organ
toxicity was deﬁned as a) O2 requirement at BMT/prior venti-
lation, b) FEV1 or FVC  60% predicted, c) Bilirubin 50 mM
or ALT 4 x normal or d) TPN dependent enteropathy. The
conditioning regimen consisted of Alemtuzumab 0.2mg/kg x 3
(MUD) or 0.1mg/kg x 3 (MSD) on D-8 to –6, YTH 24.5/54.12
0.4mg/kg on D-5 to D-2, with Fludarabine 150mg/m2 and
Cyclophosphamide 1200mg/m2. GVHD prophylaxis was with
CSA and MMF. Stem cell source was PBSC in 5/14 patients,
BM in 8/14 and cord blood in 1/14.
The Mabs were well tolerated. Median time to neutrophil recov-
ery  0.5  109/L was 9 days (range 0-15). The patient who
received a MMUD cord blood graft rejected. 12/13 evaluable
patients who received BM/PBSC engrafted. 7/13 patients achieved
100% donor chimerism, 4/13 high level mixed chimerism (MC) in
both myeloid and lymphoid lineages and 1/13 low level MC. Six
patients developed signiﬁcant aGVHD (3 grade 2, 3 grade 3). Since
BM has been used as the stem cell source, only 1/8 has had
GVHD  grade 3. 4/10 evaluable patients have cGVHD (limited
n2;extensive n2). At a median follow up of 13 months, all
patients are alive. 12/13 are stably engrafted and those with  6
months follow-up have good immune reconstitution. In summary,
Mab-based conditioning is well tolerated and achieves engraftment
even in patients with severe organ toxicity or DNA repair defects,
with a short period of neutropenia. The protocol enables trans-
plantation in patients who previously would not be candidates for
such a procedure and may additionally reduce late effects.
76
REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTION FOL-
LOWED BY TARGETED CONSOLIDATION IMMUNOTHERAPY WITH
GEMTUZUMAB OZOGAMICIN IN CHILDREN AND ADOLESCENTS WITH
CD33 ACUTE MYELOID LEUKEMIA
Roman, E.1, Cooney, E.1, Militano, O.1, Wolownik, K.1, Hawkes, R.1,
Foley, S.1, Satwani, P.1, Guerra, J.1, Bhatia, M.1, Bradley, B.1,
George, D.1, Garvin, J.1, Baxter-Lowe, L.A.5, Schwartz, J.2,
Cheung, Y.-K.3, van de Ven, C.1, Cairo, M.S.1,2,4 1Department of
Pediatrics; 2Pathology; 3Biostatistics; 4and Medicine, New York Presby-
terian, Columbia University, New York, NY; 5Department of Immu-
nogenics, UCSF, San Francisco, CA.
Oral Presentations30
